Bone marrow (BM) angiogenesis has an important role in the initiation and progression of multiple myeloma (MM). We looked at novel mechanisms of vessel formation in patients with MM through a comparative proteomic analysis between BM endothelial cells (ECs) of patients with active MM (MMECs) and ECs of patients with monoclonal gammopathy of undetermined significance (MGECs) and of subjects with benign anemia (normal ECs). Four proteins were found overexpressed in MMECs: filamin A, vimentin, a-crystallin B and 14-3-3f/d protein, not yet linked to overangiogenic phenotype. These proteins gave a typical distribution in the BM of MM patients and in MMECs versus MGECs, plausibly according to a different functional state. Their expression was enhanced by vascular endothelial growth factor, fibroblast growth factor 2, hepatocyte growth factor and MM plasma cell conditioned medium in step with enhancement of MMEC angiogenesis. Their silencing RNA knockdown affected critical MMEC angiogenesis-related functions, such as spreading, migration and tubular morphogenesis. A gradual stabilization of 14-3-3f/d protein was observed, with transition from normal ECs to MGECs and MMECs that may be a critical step for the angiogenic switch in MMECs and maintenance of the cell overangiogenic phenotype. These proteins were substantially impacted by anti-MM drugs, such as bortezomib, lenalidomide and panobinostat. Results suggest that these four proteins could be new targets for the antiangiogenic management of MM patients.
Introduction
In patients with multiple myeloma (MM), the emergence of a neoplastic plasma cell clone involves genetic lesions, that is, translocations between immunoglobulin (Ig) enhancers and oncogenes, and secondary events including activation of bidirectional tumor-microenvironment interactions (Kuehl and Bergsagel, 2002) . In this context, plasma cells function as primary inducers of angiogenesis and are crucial in the activation of bone marrow stromal cells, including endothelial cells (ECs), osteoclasts, fibroblasts, macrophages and mast cells, via production of major angiogenic factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2) and hepatocyte growth factor (HGF; Ribatti et al., 2006) . Activated BM stromal cells then support plasma cell growth and survival. Reciprocal positive and negative interactions between plasma cells and BM stromal cells, via cytokines, receptors and adhesion molecules, contribute to enhanced angiogenesis, which is the constant hallmark of patients with active MM but not of those with monoclonal gammopathies of undetermined significance (MGUS; Vacca et al., 1994) .
Angiogenesis occurs as a multistep process in which transcription and signaling pathway activation are needed for structural reorganization, proliferation, acquisition of the invasive phenotype and formation of vascular sprouts by MM ECs (MMECs). Activated MMECs are endowed not only with enhanced angiogenesis but also with proliferative advantage over normal ECs, which implies resistance to apoptosis and genome instability (Vacca et al., 2003; Ria et al., 2009) . Accordingly, several essential pathways regulating cytoskeletal organization, cell mitosis and apoptosis are altered in these cells.
Despite our knowledge of the basic steps involved in MM angiogenesis, further elucidation of their molecular and cell signaling events are warranted to better understand the mechanisms that lead to the transformation of MGUS ECs (MGECs) into MMECs and to the development of multicellular invading vascular sprouts in normal ECs, hence MM angiogenesis. Knowledge of global changes in MMECs' proteome in active disease may be critical to elucidate these molecular mechanisms. Although gene microarray-based profiling of MMECs versus MGECs and normal ECs revealed a role of the identified genes in the regulation of extracellular matrix formation, cell adhesion, chemotaxis, angiogenesis and resistance to apoptosis (Ria et al., 2009) , the relationships between mRNA production and protein synthesis is not closely correlated. Here, we compare MMEC with MGEC protein expression profiles, and identify four constantly overexpressed proteins in MMECs: filamin A (FLNA), vimentin (VIM), a-crystallin B (CRYAB) and 14-3-3z/d protein (YWHAZ) not yet previously correlated with overangiogenic activity. FLNA and VIM are cytoskeletal proteins governing cell adhesion and spreading (Kim et al., 2010) , CRYAB is a small heat shock protein (HSP) with antiapoptotic activity (Hishiya and Takayama, 2008) and YWHAZ is a 'scaffold' protein implicated in the regulation of a large spectrum of signaling pathways (Morrison, 2009) . We demonstrate that these proteins are essential for MMEC adhesion, migration and enhanced angiogenesis, and that they may be envisaged as targets for antiangiogenic purposes in MM patients.
Results

Four proteins are upregulated in MMECs versus MGECs and normal ECs
The SDS-polyacrylamide gel electrophoresis analysis of total proteins from normal ECs, MGECs and MMECs constantly showed six bands differentially expressed in MMECs (Figure 1 ): five proteins were upregulated and one downregulated by KODAK software analysis (difference X2 or o2). Identification of the bands by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry revealed that FLNA, VIM, CRYAB, YWHAZ and HSP90b were the upregulated proteins, whereas the one downregulated was annexin VI (ANXA6; Supplementary Table 1) . Subsequent validation by western blot confirmed upregulation for FLNA, VIM, CRYAB and YWHAZ (Figure 2a) , whereas HSP90b and ANXA6 did not show differences between the EC cell types (Supplementary Figure 1) . Fluorescence-activated cell sorting analysis further proved the FLNA, VIM, CRYAB and YWHAZ overexpression in MMECs (Figure 2b ). The expression of the four proteins in MMECs did correlate neither with the D&S stage nor with the A/B status. Real time reverse transcriptase PCR demonstrated upregulation of FLNA, VIM and CRYAB mRNA but, surprisingly, YWHAZ mRNA expression overlapped between MGECs and MMECs (Figure 2c ), suggesting that YWHAZ protein is upregulated at post-transcriptional level in MMECs.
The four proteins show different localization and distribution patterns in MMECs versus MGECs
The protein localization in MM BM biopsies was assessed by immunohistochemistry ( Figure 3 ). FLNA and VIM stained intensely and diffusely the MM microvessels (Figures 3a-d, respectively) . Of note, FLNA also recognized some stromal cells resembling macrophages and/or fibroblasts (Figure 3b , insert), whereas VIM also stained the plasma cells (Figure 3d , insert). CRYAB partially stained MM neovessels (Figures 3e and f) , plausibly those parts formed by sprouting-tip MMECs, that is, dividing and migrating cells involved in tubulogenesis (Figure 3f ). The CRYAB was also expressed by megakaryocytes (Figures 3e and f, arrows) . YWHAZ expression overlapped that of CRYAB on neovessels (Figures 3g and h) , and it was also weakly found on some plasma cells (Figure 3h , arrowheads). Similar pictures were obtained in the in vivo NOD-scid IL2rg null mice intravenously injected with the MM144 MM human cell line (Supplementary Figure 2) .
To verify whether a different subcellular distribution did exist between MMECs and MGECs, the confocal dual immunofluorescence of proteins (red signal) and actin (green signal) was conducted (Figure 4) . FLNA fluorescence was found in MGECs, forming filamentous structures distributed in the cytoplasm and more thickened ones in the perinuclear region ( Figure 4a) ; in contrast, a marked uniform protein expression was observed throughout the MMEC cytoplasm (Figure 4d) , often close to cell-cell contact regions. Interestingly, the colocalization FLNA/actin was detected in MMECs but not in MGECs (Figures 4c and f) . VIM displayed a filamentous and regular appearance in MGECs (Figure 4g ), whereas MMECs gave patchy-like accumulations or filamentous bundles, which were fragmented and irregularly scattered in the cytoplasm (Figures 4l  and m) . CRYAB showed small aggregates in the MGEC Figure 1 Coomassie blue staining SDS-polyacrylamide gel electrophoresis gel of EC lysates from a representative subject with benign anemia (normal ECs) and patients with MGUS (MGECs) and MM (MMECs). Bands differentially expressed in MMECs (ringed bands) were excised and submitted to matrixassisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for protein characterization. Protein expression is regulated by angiogenic factors and plasma cell conditioned media MMECs showed a gradual increase in tube network formation in the matrigel assay in response to serumfree medium versus VEGF plus FGF2 plus HGF versus MM plasma cell conditioned medium (CM; Figure 5a ). To investigate whether the protein expression correlated in step with MMECs angiogenesis, the effects of the above angiogenic factors and plasma cell CM on the four protein cellular content was analyzed by western blot. We observed that expression of FLNA, VIM, CRYAB and YWHAZ was further enhanced in MMECs exposed to the VEGF/FGF2/HGF-containing medium and even more in cells exposed to the plasma cell CM (Figure 5b ). Data suggest that expression of the four proteins and angiogenesis increase together in MMECs in response to both VEGF/FGF2/HGF and MM plasma cell CMs, the latter being a mixture of numerous angiogenic factors.
Knockdown of proteins inhibits tubular morphogenesis in vitro
To provide evidence on the roles of FLNA, VIM, CRYAB and YWHAZ in MMEC angiogenesis, we knocked down their genes by silencing RNA (siRNA). In FLNA-siRNA MMECs, the protein was reduced by over 70% versus untreated or non-targeted siRNA cells (Figure 6a ). FLNA-siRNA neither affected cell viability ( Figure 6a ) nor induced apoptosis (data not shown), but impacted cell spreading (À60%) and chemotaxis (À50%). The FLNA-siRNA MMECs seeded onto the matrigel surface (which mimics the subendothelial basement membrane) gave no angiogenesis, that is, it lost the arborized constitutive assembly with significant reduction in the vessel areas and length ( Figure 6a ). The VIM-siRNA MMECs revealed over 80% protein reduction (Figure 6b ). Cells were affected neither for viability ( Figure 6b ) nor apoptosis (data not shown), but showed a 60% decrease in spreading and 70% in chemotaxis with a significant block in angiogenesis ( Figure 6b ). The CRYAB-siRNA MMECs gave Figure 4c) . In contrast, YWHAZ-siRNA normal ECs revealed up to 60% protein reduction: this impacted cell viability (À70%), spreading (À43%), chemotaxis (À70%) and angiogenesis ( Figure 6d ), but not apoptosis (data not shown).
Effects of anti-MM drugs on the four proteins
Western blot analysis of MMECs exposed to these drugs showed that (Supplementary Figure 5) : (i) bortezomib induced a marked upregulation ( þ 70%) of CRYAB, a significant reduction (À57%) of VIM, and no effects on FLNA and YWHAZ; (ii) lenalidomide reduced 
Protein expression in MM plasma cells
To know whether these proteins may impact not only MM angiogenesis but also plasma cells, these cells were studied for expression in 15 patients. In contrast to
MMECs, which constantly overexpressed the proteins, plasma cells gave inconstant expression of FLNA (66% of patients), VIM (26%) and CRYAB (53%), whereas YWHAZ was present in all the patients (Supplementary Figure 6 ).
Discussion
Here, we investigated the differences in MMEC versus MGEC proteome to identify new targets for MM antiangiogenic management. We found that FLNA, VIM, CRYAB and YWHAZ are constantly overexpressed in MMECs and enhanced by VEGF, FGF2, HGF and MM plasma cell CM. These proteins are critically involved in MMEC overangiogenic phenotype and, indeed, their silencing is antiangiogenic. 
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FLNA is a ubiquitous member of the non-muscle actin-binding protein family, and a scaffold protein establishing critical links between actin and integral membrane proteins (Popowicz et al., 2006) . It is especially involved in cell adhesion, spreading and motility, as well as in signaling events (mediated by p21-activating kinase 1) regulating cytoskeletal assembly and cell shape (Vadlamudi et al., 2002) . As in MMECs, FLNA is upregulated in human tumor cells (Zhou et al., 2010) , while it not defined as oncogenic protein. FLNA intensely stains numerous neovessels in the BM of MM patients, and is abundantly distributed in MMEC cellular protrusions, like to what happens in invading and migrating prostate cancer cells (Bedolla et al., 2009) . Its knockdown affects MMEC spreading and migration in agreement with what has been observed in FLNAdeficient human embryo kidney cells and fibroblasts (Kim et al., 2010) . It also inhibits MMEC angiogenic activity as found in FLNA-deficient mice whose vessels are disorganized and show abnormal adherent junctions with simultaneous vascular endothelial-cadherin downregulation (Feng et al., 2006) .
VIM is a widely expressed mammalian intermediate filament protein closely involved in cell adhesion, migration and signaling (Eriksson et al., 2009) . Its overexpression has been observed in several human tumor cells (Matrone et al., 2010) and generally in cells with growing and metastatic phenotype (DutschWicherek, 2010) akin to overangiogenic MMECs, but it is not defined as an oncogene. VIM is highly positive in MM BM neovessels and, at variance with MGECs, it is disassembled in the cytoplasm and cellular protrusions of MMECs. Similar pictures have been described in fibroblasts and ECs in response to platelet-derived growth factor and epidermal growth factor (Meriane et al., 2000) . The VIM disassembly implies its phosphorylation (Chan et al., 2002 ) that positively mediates cell adhesion, motility and signaling. Accordingly, we showed that the VIM knockdown inhibits MMECs spreading and migration, similarly to VIM-silenced fibroblasts and epithelial cells (Gilles et al., 1999) and ECs in which adhesion (Gonzales et al., 2001) and formation of focal contacts (Tsuruta and Jones, 2003) are halted. Moreover, VIM is overexpressed in rat ECs with migrating phenotype versus cells with low migratory activity (Obermeyer et al., 2003) . VIM downregulation inhibits the MMEC angiogenic activity that critically depends on cell spreading and migration.
CRYAB is a small HSP generally needed for maintenance of eye lens cells, cell protection, proteasome interactions and apoptosis inhibition (Kamradt et al., 2001) . It regulates tubular morphogenesis and EC survival during tumor angiogenesis (Dimberg et al., 2008) , that is in line with our findings in MMECs and MM neovessels. It is an oncogene highly expressed in human tumors, in which it predicts shorter survival (Moyano et al., 2006; Arrigo et al., 2007) , but it has not been described yet as oncogene in MM (Gruvberger Saal and Parsons, 2006) . Although CRYAB locates as perinuclear granules in MGECs, it gives a wellorganized cytoplasmic network in MMECs, implying a different functional attitude in these cells. The MGEC CRYAB granules are reminiscent of 'heat shock granules' formed by small HSPs (Van den IJssel et al., 2003) and of 'speckles', which are interchromatin clusters containing small nuclear ribonucleoproteins and other splicing components (Van Rijk et al., 2003) . In contrast, the CRYAB cytoplasmic distribution, as in MMECs, is associated with the Golgi apparatus and endoplasmic reticulum, where it has chaperone activity (Andley, 2007) . Of note, CRYAB stabilizes microfilaments, intermediate filaments and microtubules (Head et al., 2000) , which have an important role in EC spreading, migration and tubulogenesis. CRYAB overexpression in transformed human breast epithelial cells leads to increased cell migration and luminal filling compared with normal cells (Moyano et al., 2006) . Accordingly, the CRYAB silencing in MMECs impairs cell spreading, migration and angiogenesis but not viability. Interestingly, the lowered VIM expression in CRYAB-siRNA MMECs confirms the role of CRYAB in intermediate filaments stabilization. CRYAB has not been previously implicated in EC migration, but the highly homologous family member HSP27 regulates, at least in vitro, the migration of both ECs and smooth muscle cells (Lee et al., 2008) . Our results in MMECs agree with those of Dimberg et al. (2008) , which showed that tumor vessels in CRYAB _/_ mice have thinner and more disrupted walls than those of wild-type mice. In addition, CRYAB controls angiogenesis via post-translational regulation of VEGF secretion and, in turn, VEGF itself stimulates CRYAB phosphorylation in angiogenic ECs, suggesting a positive loop (Kase et al., 2010) . Perhaps, a similar loop is operative in MMECs that secrete high levels of VEGF (Vacca et al., 2003) and overexpress CRYAB.
YWHAZ is an oncogene and adapter/scaffold protein needed for cell signaling, cycle control and survival of tumor cells (Aitken, 2006) . It is overexpressed in several tumor cells (Morrison, 2009) , including MM plasma cells in which it has a possible oncogenic function (Lu et al., 2010) . Here, we show that it is also overexpressed in MMECs and MM neovessels. Although YWHAZ locates as perinuclear granules in MGECs, it is Angiogenic proteins of MMECs S Berardi et al distributed as a uniform cytoplasmic network colocalizing with actin in MMECs. Colocalization with actin may imply a dynamic role of YWHAZ in the regulation of actin structures. Interestingly, although MMECs and MGECs were similar for YWHAZ transcriptional level, the protein was overexpressed in MMECs. This suggests that YWHAZ expression is regulated at post-transcriptional level through modifications of mRNA stability and/or translational efficiency. Previous studies have shown no correlation between low 14-3-3s mRNA level and high 14-3-3s protein expression in vulvar carcinoma (Wang et al., 2008) . However, mutations mimicking phosphorylation (or phosphorylation itself) affect the YWHAZ structure, so that the protein becomes more or less susceptible to proteolysis or more or less stable to different unfavorable conditions (Sluchanko et al., 2008) . These changes in stability indirectly affect interactions of YWHAZ with different target proteins and regulate the protein activity in the cell. Events of this type may happen in MMECs. In fact, we found that a large YWHAZ mRNA decrease (by siRNA) resulted in only marginal reduction (B10%) of the protein content in MMECs even at 7 days after transfection, with no effects on the angiogenesis-related cell functions and angiogenesis itself. When we silenced MGECs and normal ECs, we obtained a greater protein reduction (À30% and À60%, respectively), with a progressive impairment of their angiogenic ability. Indeed, normal ECs were inhibited in viability, which agrees with the supporting role of YWHAZ to the G2-M phase transition (Fan et al., 2007) . EC spreading was also inhibited in agreement with the role of the protein in cell anchorage to the matrix (Li et al., 2008) . We hypothesize that a gradual protein stabilization takes place in MMECs in step with transformation from MGECs or normal ECs, and that the high level of stabilization in MMECs may be a key step for the angiogenic switch and maintenance of angiogenesis in MM.
These proteins were targeted by antiangiogenic drugs used in MM patients, such as bortezomib and lenalidomide, and by the novel anti-MM drug panobinostat.
The protein expression was also investigated in BM plasma cells from 15 MM patients: FLNA, VIM and CRYAB were inconstantly expressed, whereas YWHAZ was always present. These data suggest that YWHAZ could be a preferential target for both MMECs and MM plasma cells as demonstrated previously (Ge et al., 2009) , whereas the other proteins should be characterized in each patient to target plasma cells.
Overall, these findings confirm that MMECs are overangiogenic compared with MGECs and normal ECs, and indicate that their overangiogenic activity is linked to a well-defined protein expression. This proteomic signature renders MMECs very similar to transformed (such as tumor) cells than normal ECs. The MMECs' similarity to tumor cells has been also hypothesized in studies at the genomic level (Ria et al., 2009) . As overexpression of FLNA, VIM, CRYAB and YWHAZ in MMECs has a key role in determining their overangiogenic phenotype, and as their silencing is antiangiogenic, these proteins could be considered new targets for molecular therapy in MM patients. Finally, as MMECs are analyzed B30 days after harvesting from the BM, we suggest, tentatively, that changes in genes (FLNA, VIM and CRYAB) and proteins (YWHAZ) are stably acquired by these cells, with transition from MGUS (avascular phase) to MM (vascular phase). Perhaps these gene/protein changes are a consequence of genomic or epigenetic (dysregulation in DNA methylation?) changes. Stable epigenetic changes in ECs have been already described in mice tumor models (Hellebrekers et al., 2006) . However, literature data show that little characterization of MM at the epigenetic level (for example gene methylation and acetylation) has been performed (Kuehl and Bergsagel, 2002) . How plasma cells, other microenvironment cells and extracellular matrix components concur to the epigenetic changes may be an object for future investigation.
Materials and methods
Patients and ECs
Patients fulfilling the International Myeloma Working Group diagnostic criteria for active MM (n ¼ 26) and MGUS (n ¼ 18) were studied. MM patients (15 men and 11 women) were aged 45-82 years (median 63.5 years) and D&S staged as IIA (n ¼ 5), IIB (n ¼ 3), IIIA (n ¼ 14) and IIIB (n ¼ 4); the Mcomponent was IgG (n ¼ 16), IgA (n ¼ 6), and k or l (n ¼ 4). MGUS patients (11 men and 7 women) were aged 42-79 years (median 60.5 years) and were IgG (n ¼ 12), IgA (n ¼ 4) or k or l (n ¼ 2). Normal (control) ECs were derived from 12 subjects with anemia due to iron or vitamin B 12 deficiency (Vacca et al., 1994) . As ECs are phenotypically and functionally site restricted (Aird, 2007) we analyzed these cells from the BM in both patients and controls. The normal ECs were little heterogeneous in terms of expression of FLNA, VIM, CRYAB and YWHAZ because the s.d. of the SDS-polyacrylamide gel electrophoresis band reading (as optical density, see 'Western blot and real-time reverse transcriptase PCR validation') was marginal. Actually, the optical density ± s.d. values were: FLNA 12 000±1000, VIM 10 000±600, CRYAB 6000±300 and YWHAZ 3000±500. Moreover, expression of FLNA, VIM, CRYAB and YWHAZ in ECs from the anemic subjects overlapped with that seen in human umbilical vein ECs (American type culture collection, Manassas, WA, USA) studied as a further normal control (data not shown). The study was approved by the Ethics Committee of the University of Bari Medical School, and all patients gave informed consent according to the Declaration of Helsinki.
BM primary MMECs, MGECs and normal ECs were obtained as described (Vacca et al., 2003) . MM plasma cells were obtained by CD38-coated beads (Coluccia et al., 2008) .
Protein expression profiling by one-dimensional gel electrophoresis Total EC protein lysates were quantified with the Bradford assay (Bio-Rad, Hercules, CA, USA). Each sample (100 mg) was separated on a 10% SDS-polyacrylamide gel electrophoresis under reducing conditions. Gels stained with Coomassie Blue R-250 (Bio-Rad) were scanned using the Gel Logic 1500 Imaging System (Eastman Kodak Co., Rochester, NY, USA), and digitally imaged with the Kodak Molecular Imaging Software. Internal standards (Precision Plus Protein, Bio-Rad) were used.
In-gel digestion and protein identification Differentially selected protein spots were excised from the gel, destained and in-gel digested (Shevchenko et al., 2006) . The trypsinized peptide mixtures were analyzed with MALDI-TOF Voyager DE-STR spectrometer (Applied Biosystems, Framingham, MA, USA) and a 337-nm nitrogen laser and operating in reflector mode. Mass spectrometry external calibration was conducted for all spectra. Peptide mass fingerprinting was performed against SwissProt database and MASCOT 2.3 algorithm (http://www.matrixscience.com/).
Fluorescence-activated cell sorting Confluent MMECs and MGECs were fixed with 0.5% paraformaldehyde (Sigma Chemical Co., St Louis, MO, USA). A total of 3 Â 10 5 cells/tube were incubated with a phycoerythrin-labeled anti-CD105 antibody (Beckman Coulter, Brea, CA, USA) in PBS 1 Â with 5% FCS (buffer A). Cells were fixed with 2% paraformaldehyde, washed in buffer A, permeabilized with saponin 0.5% (permeabilization buffer) and incubated with anti-FLNA (Epitomics, Burlingame, CA, USA), anti-VIM (Cell Marque, Rocklin, CA, USA), anti-CRYAB and anti-YWHAZ (Abcam, Cambridge, UK) and isotype matched control antibodies. Fluorescein isothiocyanate anti-mouse or anti-rabbit antibodies were added to the permeabilization buffer. At least 50 000 CD105-positive events per sample were analyzed using FACScantoII (Becton Dickinson, San Jose, CA, USA). The expression levels were calculated as mean fluorescence intensity ratio of the antibodies divided by mean intensity of the controls.
Western blot and real-time reverse transcriptase PCR validation Total protein lysates (30 mg) from MMECs, MGECs, and MGUS or MM plasma cells were separated on 4-12% NuPAGE gels (Invitrogen Corp., Carlsbad, CA, USA), electrotransferred to a polyvinylidene difluoride membrane (PerkinElmer Life Science Inc., Boston, MA, USA) and immunoblotted with anti-FLNA, anti-VIM (ChemiCon Corp., Nuremberg, Germany), anti-YWHAZ (Cell Signaling Technology, Danvers, MA, USA), anti-CRYAB (Abcam, Cambridge, UK) and anti-b-actin or anti-tubulin (Sigma-Aldrich, St Louis, MO, USA). Then the membranes were incubated with horseradish peroxidase-labeled secondary antibody (Bio-Rad). Immunoreactive bands were detected using the enhanced chemiluminescence kit (LiteAblot, Euroclone, Milan, Italy) and the Gel-Logic1500 System (Eastman Kodak Co.), quantified by the Kodak Imaging Software and expressed as optical density units.
Real time reverse transcriptase PCR was performed as described (Ria et al., 2009 ) using primers (Invitrogen, Paisley, UK; Supplementary Table 2) and the Applied Biosystems methodology. Relative quantification of the mRNA level was performed using the comparative Ct method with GAPDH as the reference gene and with the 2 ÀDDCT formula (Livak and Schmittgen, 2001 ).
Immunohistochemistry and dual immunofluorescence-confocal laser scanning microscopy Formalin-fixed, 4 mm-thick BM sections of MM patients were stained with anti-FLNA (Lifespan Biosciences, Seattle, WA, USA), anti-VIM (Cell Marque), anti-CRYAB and anti-YWHAZ (Abcam) antibodies using a biotin-streptavidin method (Coluccia et al., 2008) .
For confocal microscopy, 5 Â 10 3 MMECs or MGECs were cultured on fibronectin-coated chamber slides (LabTek, Nalge Nunc International, Naperville, IL, USA), fixed with 2% paraformaldehyde and incubated with the above antibodies, then incubated with the corresponding Alexa Fluor555 goat anti-mouse or anti-rabbit IgG antisera (Invitrogen Corp.). Nuclei were counterstained with TO-PRO-3 iodide (Invitrogen Corp.), whereas actin was marked with phalloidin (SigmaAldrich). Negative controls were obtained by substituting primary antibodies with normal mouse or rabbit serum (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
RNA interference
MMECs (4 Â 10 5 ) were transiently transfected with: (i) VIMsiRNA 10 nM or CRYAB-siRNA 25 nM for 3 days; (ii) FLNA-siRNA or YWHAZ-siRNA both 10 nM for 5 or 7days respectively; (iii) control siRNAs (SMART-pool; Dharmacon RNA Technologies, Lafayette, CO, USA); or (iv) the transfection reagent alone (Lipofectamine RNAiMAX siRNA transfection reagent, Invitrogen Corp.). MGECs and normal ECs were transfected with YWHAZ-siRNA 10 nM from 3 to 7 days and for 3 days respectively.
Functional studies Viability and apoptosis. Viability was assessed by trypan blue staining. The apoptotic cell rate was detected with the Apoptosis Detection Kit (Becton Dickinson): 5 Â 10 5 siRNAtransfected MMECs, MGECs or normal ECs were incubated with phycoerythrin-annexin V and 7-amino-actinomycin D, and analyzed by the FACScantoII on at least 10 000 events per sample.
Adhesion. In all, 1 Â 10 4 siRNA-transfected MMECs were plated in Dulbecco's modied Eagle's medium (DMEM) (Euroclone) on fibronectin-coated or not coated (negative control) 96-well plates in triplicate, fixed with 4% formaldehyde at 90 min and quantified by the crystal violet assay at 595 nM in a Microplate Reader (Molecular Devices Corp., Sunnyvale, CA, USA; Podar et al., 2001) .
Chemotaxis. In all, 5 Â 10 4 siRNA-transfected ECs were seeded on the upper compartment of a Boyden microchamber on a micropore nitrocellulose filter (8 mm pores) towards a medium with 1.5% serum and with or without (negative control) VEGF (10 ng/ml, Sigma Chemical Co.) and FGF2 (10 ng/ml, Peprotech Inc., Rocky Hill, NJ, USA) in the lower compartment (Coluccia et al., 2008) . After 6 h at 37 1C, the migrated ECs were fixed, stained (SNABB-DIFF Kit, Labex AB, Helsingborg, Sweden) and counted by the EVOS inverted microscope (Euroclone) at Â 400.
Angiogenesis. MMECs (2 Â 10 4 ) were plated on Matrigelcoated (Becton Dickinson) 96-well plates in serum-free medium or DMEM supplemented with 15 ng/ml VEGF, HGF (Sigma Chemical Co.) and FGF2 or CM of plasma cells from the MM patients. A total of 2 Â 10 4 siRNAtransfected ECs/well were seeded on the matrigel plates in DMEM with VEGF 10 ng/ml. After 6 h, the skeletonization of the mesh was followed by measurement of mesh areas and vessel length with EVOS (Euroclone) at Â 200 (De Luisi et al., 2011) . Each individual experiment of all assays had triplicate inserts, and three microscopic fields/insert were counted.
